Back to results
US 6,281,363 B1Granted
Cyclic hydrazine derivatives
AssigneeHoffmann-La Roche Inc.
InventorsMichael John Broadhurst, William Henry Johnson, Daryl Simon Walter
Life of this patent
Estimating the term…
Abstract
Hydrazine derivatives and their pharmaceutically acceptable salts useful for the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular disease, fever, hemorrhage, and sepsis.
Claims16
A hydrazine derivative, being a compound of the formula
- wherein the ring incorporating W, X, Y, and Z is selected from the group consisting of rings of formulae (a), (b), (c), (d), (e), (f), (g), (h), (i), (u),
- and
- R1 is unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted lower cycloalkyl, unsubstituted lower cycloalkyl-lower alkyl, unsubstituted or substituted phenyl or naphthyl, or phenyl- or naphthyl-lower alkyl in which the phenyl or naphthyl is unsubstituted or substituted and the lower alkyl is unsubstituted;
- R2 is unsubstituted lower alkyl, unsubstituted lower alkenyl, unsubstituted lower cycloalkyl, unsubstituted lower cycloalkyl-lower alkyl, —V-phenyl or -naphthyl in which the phenyl or naphthyl is unsubstituted or substituted, —V-heterocyclyl in which the heterocyclyl is unsubstituted or substituted, or —(CH2)q—CH═CR8R9;
- R3, R4, R5, R6 and R7 are each independently hydrogen, unsubstituted or substituted lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl in which the lower alkyl is unsubstituted and the cycloalkyl is unsubstituted, unsubstituted or substituted phenyl or naphthyl, phenyl- or naphthyl-lower alkyl in which the phenyl or naphthyl is unsubstituted or substituted and the lower alkyl is unsubstituted, unsubstituted or substituted heterocyclyl or heterocyclyl-lower alkyl in which the heterocyclyl is unsubstituted or substituted and the lower alkyl is unsubstituted;
- except that R3 and R4 cannot both be hydrogen, or R3 and R4 together with the carbon atom to which they are attached form a saturated carbocyclic ring having from 3 to 8 ring atoms in which zero or one ring atom is a heteroatom selected from the groups consisting of N, O and S wherein the ring nitrogen is unsubstituted or substituted;
- or R5 and R6 or R5 and R7 together with the nitrogen atoms to which they are attached form a saturated carbocyclic ring having from 3 to 8 ring atoms;
- or R11 and R12 together with the sp2 carbon atoms to which they are attached form a fused unsubstituted lower cycloalkenyl, unsubstituted or substituted phenyl or naphthyl or unsubstituted or substituted heteroaryl;
- or R5 with either R13 or R14 together are lower alkylene in which zero or one CH2 of the lower alkylene is replaced by a heteroatom selected from the group consisting of N, O and S wherein the N is unsubstituted or substituted;
- or either R6 or R7 with either R3 or R4 together are lower alkylene in which zero or one CH2 of the lower alkylene is replaced by a heteroatom selected from the group consisting of N, O and S wherein the N is unsubstituted or substituted;
- V is —(CH2)r—U—(CH2)s— in which r and s are each independently 0, 1, 2 or 3 and wherein U is absent or is —CH═CH—, —C≡C—, —S—, —O—, —NH—, NHCO—, —CONH—, —SO2—, —NHSO2—, —SO2NH—, —NHCONH— or —NHSO2NH—;
- R8 and R9 together are lower alkylene in which zero or one CH2 of the lower alkylene is replaced by a heteroatom selected from the group consisting of N,O and S wherein the N is unsubstituted or substituted;
- and
- q is 1 or 2;
- or a mixture containing the compound and one or more optical isomers thereof, or a pharmaceutically acceptable salt of said compound or said mixture.
12 more elements
Dependencies are inferred from the claim text.